e-learning
resources
European Respiratory Review
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators
Stefano Ponzano, Giulia Nigrelli, Laura Fregonese, Irmgard Eichler, Fabio Bertozzi, Tiziano Bandiera, Luis J.V. Galietta, Marisa Papaluca
Source:
Eur Respir Rev, 27 (148) 170124; 10.1183/16000617.0124-2017
Journal Issue:
June
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Stefano Ponzano, Giulia Nigrelli, Laura Fregonese, Irmgard Eichler, Fabio Bertozzi, Tiziano Bandiera, Luis J.V. Galietta, Marisa Papaluca. A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators. Eur Respir Rev, 27 (148) 170124; 10.1183/16000617.0124-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions
Definition and history of sarcoidosis
Related content which might interest you:
ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies
Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020
Year: 2020
The era of CFTR modulators: improvements made and remaining challenges
Source: Breathe, 16 (2) 200016; 10.1183/20734735.0016-2020
Year: 2020
CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways
Source: Eur Respir Rev, 29 (156) 190068; 10.1183/16000617.0068-2019
Year: 2020
Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy
Source: Breathe, 17 (4) 210112; 10.1183/20734735.0112-2021
Year: 2021
Gene therapy for cystic fibrosis: successes and challenges
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=79
Year: 2006
The cystic fibrosis transmembrane conductance regulator and its modulators: clinical implications
Source: Virtual Congress 2020 – Respiratory infections
Year: 2020
Treatment of interstitial lung diseases: current approaches and future directions
Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options
Year: 2021
COPD mechanisms: novel aspects and implications for new therapies
Source: ERS Live 2007
Year: 2007
Idiopathic pulmonary fibrosis: current challenges and future perspectives
Source: Eur Respir Rev 2013; 22: 103-105
Year: 2013
Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis
Source: Eur Respir Rev 2013; 22: 58-65
Year: 2013
How organoids helped to discover cystic fibrosis transmembrane conductance regulator (CFTR) therapeutics and predict response to treatment
Source: International Congress 2016 – Closing the gap: novel translational research strategies
Year: 2016
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
Source: Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017
Year: 2017
Can different approaches to anti-inflammatory therapy result in different outcomes in cystic fibrosis patients?
Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know?
Year: 2007
Genomically-guided therapies: a new era for cystic fibrosis
Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases
Year: 2020
Possible mechanisms of action of azithromycin in cystic fibrosis
Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle
Year: 2005
Pharmacological treatment of the biochemical defect in cystic fibrosis airways
Source: Eur Respir J 2001; 17: 1314-1321
Year: 2001
CF clinical care and its delivery: current and future challenges
Source: International Congress 2019 – Future of cystic fibrosis care: insights from the Lancet Commission
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept